Cargando…

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report

BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. CASE PRESENTATION: A 65-year-old man who was diagnosed with PCS was tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimoto, Azusa, Takeuchi, Shinji, Kotani, Hiroshi, Yamashita, Kaname, Yamada, Tadaaki, Ohtsubo, Koushiro, Ebi, Hiromichi, Ikeda, Hiroko, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291996/
https://www.ncbi.nlm.nih.gov/pubmed/30541518
http://dx.doi.org/10.1186/s12890-018-0757-7
_version_ 1783380324127866880
author Tanimoto, Azusa
Takeuchi, Shinji
Kotani, Hiroshi
Yamashita, Kaname
Yamada, Tadaaki
Ohtsubo, Koushiro
Ebi, Hiromichi
Ikeda, Hiroko
Yano, Seiji
author_facet Tanimoto, Azusa
Takeuchi, Shinji
Kotani, Hiroshi
Yamashita, Kaname
Yamada, Tadaaki
Ohtsubo, Koushiro
Ebi, Hiromichi
Ikeda, Hiroko
Yano, Seiji
author_sort Tanimoto, Azusa
collection PubMed
description BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. CASE PRESENTATION: A 65-year-old man who was diagnosed with PCS was treated by surgical removal of the primary lung lesion, followed by six cycles of adjuvant chemotherapy with cisplatin plus irinotecan. Following the chemotherapy, he experienced a relapse with brain metastasis, which induced the rapid onset of left leg paralysis. Radical surgical resection and stereotactic radiosurgery to the resection cavity were performed. However, meningeal dissemination and new lung metastases occurred after a year and half. To control these multiple metastatic lesions, the patient was treated with the multiple kinase inhibitor pazopanib. No change was observed in the meningeal dissemination, while the metastatic lung lesions were prominently reduced in size following treatment with pazopanib. Consequently, the patient showed a partial response to pazopanib treatment, although the dose of pazopanib was reduced by half as a result of thrombocytopenia. CONCLUSION: This is the first report of metastatic PCS showing an evident therapeutic response to tumor-targeted therapy. We suggest that pazopanib may be a therapeutic option for patients with metastatic PCS.
format Online
Article
Text
id pubmed-6291996
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62919962018-12-17 Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report Tanimoto, Azusa Takeuchi, Shinji Kotani, Hiroshi Yamashita, Kaname Yamada, Tadaaki Ohtsubo, Koushiro Ebi, Hiromichi Ikeda, Hiroko Yano, Seiji BMC Pulm Med Case Report BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. CASE PRESENTATION: A 65-year-old man who was diagnosed with PCS was treated by surgical removal of the primary lung lesion, followed by six cycles of adjuvant chemotherapy with cisplatin plus irinotecan. Following the chemotherapy, he experienced a relapse with brain metastasis, which induced the rapid onset of left leg paralysis. Radical surgical resection and stereotactic radiosurgery to the resection cavity were performed. However, meningeal dissemination and new lung metastases occurred after a year and half. To control these multiple metastatic lesions, the patient was treated with the multiple kinase inhibitor pazopanib. No change was observed in the meningeal dissemination, while the metastatic lung lesions were prominently reduced in size following treatment with pazopanib. Consequently, the patient showed a partial response to pazopanib treatment, although the dose of pazopanib was reduced by half as a result of thrombocytopenia. CONCLUSION: This is the first report of metastatic PCS showing an evident therapeutic response to tumor-targeted therapy. We suggest that pazopanib may be a therapeutic option for patients with metastatic PCS. BioMed Central 2018-12-12 /pmc/articles/PMC6291996/ /pubmed/30541518 http://dx.doi.org/10.1186/s12890-018-0757-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Tanimoto, Azusa
Takeuchi, Shinji
Kotani, Hiroshi
Yamashita, Kaname
Yamada, Tadaaki
Ohtsubo, Koushiro
Ebi, Hiromichi
Ikeda, Hiroko
Yano, Seiji
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
title Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
title_full Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
title_fullStr Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
title_full_unstemmed Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
title_short Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
title_sort pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291996/
https://www.ncbi.nlm.nih.gov/pubmed/30541518
http://dx.doi.org/10.1186/s12890-018-0757-7
work_keys_str_mv AT tanimotoazusa pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT takeuchishinji pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT kotanihiroshi pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT yamashitakaname pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT yamadatadaaki pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT ohtsubokoushiro pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT ebihiromichi pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT ikedahiroko pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport
AT yanoseiji pulmonarycarcinosarcomashowinganobviousresponsetopazopanibacasereport